Todd Asset Management LLC Has $974,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Todd Asset Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 95.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,023 shares of the biopharmaceutical company’s stock after selling 273,340 shares during the period. Todd Asset Management LLC’s holdings in Gilead Sciences were worth $974,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Clearbridge Investments LLC boosted its stake in Gilead Sciences by 179.0% in the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after acquiring an additional 2,915,141 shares during the last quarter. abrdn plc grew its holdings in shares of Gilead Sciences by 89.0% in the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after buying an additional 1,772,887 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $133,584,000. AEGON ASSET MANAGEMENT UK Plc acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $63,971,000. Finally, Van ECK Associates Corp grew its holdings in shares of Gilead Sciences by 18.3% in the 3rd quarter. Van ECK Associates Corp now owns 4,534,839 shares of the biopharmaceutical company’s stock valued at $339,841,000 after buying an additional 702,342 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $0.55 during trading on Friday, reaching $64.78. 7,822,720 shares of the company’s stock were exchanged, compared to its average volume of 7,345,331. Gilead Sciences, Inc. has a fifty-two week low of $64.33 and a fifty-two week high of $87.86. The stock has a market capitalization of $80.66 billion, a P/E ratio of 179.94, a PEG ratio of 1.31 and a beta of 0.22. The business has a 50 day moving average price of $70.55 and a 200-day moving average price of $75.83. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.37 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada decreased their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a report on Friday, April 26th. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Maxim Group cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Finally, Cantor Fitzgerald decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.